Microcephalic osteodysplastic primordial dwarfism type II is associated with global vascular disease.
Aneurysm
Chronic kidney disease
Diabetes
Kaplan–Meier
MOPDII
Moyamoya
Myocardial infarction
Primordial dwarfism
Stroke
Vascular disease
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
20 05 2021
20 05 2021
Historique:
received:
29
10
2020
accepted:
04
05
2021
entrez:
21
5
2021
pubmed:
22
5
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) is the most common form of primordial dwarfism, caused by bialleic mutations in the pericentrin gene (PCNT). Aside from its classic features, there are multiple associated medical complications, including a well-documented risk of neurovascular disease. Over the past several years, it has become apparent that additional vascular issues, as well as systemic hypertension and kidney disease may also be related to MOPDII. However, the frequency and extent of the vasculopathy was unclear. To help address this question, a vascular substudy was initiated within our Primordial Dwarfism Registry. Medical records from 47 individuals, living and deceased, ranging in age from 3 to 41 years of age were interrogated for this purpose. Of the total group, 64% were diagnosed with moyamoya, intracranial aneurysms, or both. In general, the age at diagnosis for moyamoya was younger than aneurysms, but the risk for neurovascular disease was throughout the shortened lifespan. In addition to neurovascular disease, renal, coronary and external carotid artery involvement are documented. 43% of the total group was diagnosed with hypertension, and 17% had myocardial infarctions. A total of 32% of the entire cohort had some form of chronic kidney disease, with 4% of the total group necessitating a kidney transplant. In addition, 38% had diabetes/insulin resistance. Ages of diagnoses, treatment modalities employed, and location of vasculopathies were notated as available and applicable, as well as frequencies of other comorbidities. It is now clear that vascular disease in MOPDII is global and screening of the cardiac and renal vessels is warranted along with close monitoring of blood pressure. We recommend a blood pressure of 110/70 mmHg as a starting point for an upper limit, especially if the individual has a history of neurovascular disease, chronic kidney disease and/or diabetes. Additionally, providers need to be at high alert for the possibility of myocardial infarctions in young adults with MOPDII, so that appropriate treatment can be initiated promptly in an acute situation.
Sections du résumé
BACKGROUND
Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) is the most common form of primordial dwarfism, caused by bialleic mutations in the pericentrin gene (PCNT). Aside from its classic features, there are multiple associated medical complications, including a well-documented risk of neurovascular disease. Over the past several years, it has become apparent that additional vascular issues, as well as systemic hypertension and kidney disease may also be related to MOPDII. However, the frequency and extent of the vasculopathy was unclear. To help address this question, a vascular substudy was initiated within our Primordial Dwarfism Registry.
RESULTS
Medical records from 47 individuals, living and deceased, ranging in age from 3 to 41 years of age were interrogated for this purpose. Of the total group, 64% were diagnosed with moyamoya, intracranial aneurysms, or both. In general, the age at diagnosis for moyamoya was younger than aneurysms, but the risk for neurovascular disease was throughout the shortened lifespan. In addition to neurovascular disease, renal, coronary and external carotid artery involvement are documented. 43% of the total group was diagnosed with hypertension, and 17% had myocardial infarctions. A total of 32% of the entire cohort had some form of chronic kidney disease, with 4% of the total group necessitating a kidney transplant. In addition, 38% had diabetes/insulin resistance. Ages of diagnoses, treatment modalities employed, and location of vasculopathies were notated as available and applicable, as well as frequencies of other comorbidities.
CONCLUSIONS
It is now clear that vascular disease in MOPDII is global and screening of the cardiac and renal vessels is warranted along with close monitoring of blood pressure. We recommend a blood pressure of 110/70 mmHg as a starting point for an upper limit, especially if the individual has a history of neurovascular disease, chronic kidney disease and/or diabetes. Additionally, providers need to be at high alert for the possibility of myocardial infarctions in young adults with MOPDII, so that appropriate treatment can be initiated promptly in an acute situation.
Identifiants
pubmed: 34016138
doi: 10.1186/s13023-021-01852-y
pii: 10.1186/s13023-021-01852-y
pmc: PMC8139163
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
231Références
J Am Coll Cardiol. 2019 Oct 8;74(14):1823-1838
pubmed: 31582143
Am J Epidemiol. 2016 Jan 1;183(1):79-83
pubmed: 26646294
Science. 2008 Feb 8;319(5864):816-9
pubmed: 18174396
Pediatrics. 2017 Sep;140(3):
pubmed: 28827377
Am J Med Genet A. 2004 Sep 15;130A(1):55-72
pubmed: 15368497
Curr Osteoporos Rep. 2017 Apr;15(2):61-69
pubmed: 28409412
J Med Genet. 2010 Dec;47(12):797-802
pubmed: 19643772
Am J Med Genet A. 2017 Nov;173(11):3067-3069
pubmed: 28940990
Diabetes Obes Metab. 2007 Nov;9(6):767-80
pubmed: 17924861
Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):125-30
pubmed: 21396579
Am J Med Genet A. 2010 Apr;152A(4):960-5
pubmed: 20358609
Stroke. 2000 Mar;31(3):733-7
pubmed: 10700512
Eur J Pediatr. 2003 Dec;162(12):860-2
pubmed: 14564517
Eur J Paediatr Neurol. 2016 Jan;20(1):20-4
pubmed: 26652853
Pediatr Neurol. 2013 Apr;48(4):294-8
pubmed: 23498563
N Engl J Med. 2009 Mar 19;360(12):1226-37
pubmed: 19297575
Pediatr Neurosurg. 2010;46(5):373-80
pubmed: 21389750
J Child Neurol. 2013 May;28(5):561-9
pubmed: 22832780
Am J Med Genet. 1982 May;12(1):23-35
pubmed: 7201238
Eur J Pediatr. 2014 Sep;173(9):1253-6
pubmed: 24973050
Nat Genet. 2008 Feb;40(2):232-6
pubmed: 18157127
Am J Med Genet A. 2012 Nov;158A(11):2719-25
pubmed: 22821869
Am J Med Genet A. 2006 Jun 15;140(12):1356
pubmed: 16691599
J Neurosurg Pediatr. 2009 Nov;4(5):439-44
pubmed: 19877776
J Pediatr Orthop. 2014 Sep;34(6):585-90
pubmed: 24705347
J Hum Genet. 2019 Sep;64(9):885-890
pubmed: 31270375
Am J Med Genet A. 2010 Oct;152A(10):2437-43
pubmed: 20734336
Thorac Cardiovasc Surg. 2009 Apr;57(3):169-70
pubmed: 19330756
Eur Heart J Cardiovasc Imaging. 2016 May;17(5):575
pubmed: 26864187
J Vasc Surg. 2007 Sep;46(3):475-484
pubmed: 17681709
Genes Dev. 2011 Oct 1;25(19):2011-24
pubmed: 21979914
J Neurosurg Pediatr. 2016 Dec;25(6):717-723
pubmed: 27611897
J Korean Med Sci. 2015 Apr;30(4):470-4
pubmed: 25829816
Pediatr Nephrol. 1999 May;13(4):343-6
pubmed: 10454788
Am J Med Genet A. 2011 Jun;155A(6):1398-403
pubmed: 21567919
Am J Med Genet A. 2005 Dec 15;139(3):212-5
pubmed: 16278902
Diabetes. 2011 Mar;60(3):925-35
pubmed: 21270239
AJR Am J Roentgenol. 2004 Jul;183(1):119-22
pubmed: 15208124